Are you using the right Covid-19 test? In the race to contain the COVID-19 pandemic, efficient detection of SARS-CoV-2 was and still remains the cornerstone. On January 23, the first in-house RT-PCR assay was published, quickly followed by the development of multiple commercial kits.
During the webinar, a Cerba biologist will walk participants through the overview of our serological testing, discuss the reliability of tests, the current limits in Covid-19 testing, and which sample is the most efficient in each case.
Lastly, Cerba Research’s partner Fulgent will discuss NGS testing and how much we know about the analysis of the virus and its mutations.
Join this discussion in order to help you to choose the best test for your research!
Benedicte Roquebert, PhD Biologist, Cerba Research
A microbiologist specialized in the field of Virology, Roquebert, Pharm D PhD, is member of the European Society in Clinical Microbiology and Infectious Diseases (ESCMID), the Agence Nationale de Recherche contre le SIDA et les hépatites virales (ANRS) and the French Society of Microbiology (SFM). She is a former Paris Hospitals resident and has been a junior medical virologist at Bichat Claude Bernard Hospital in Paris for 4 years. From 2014 to 2019, she was a university hospital virology lecturer, deputy director of the arbovirus infection’s associate reference center and head of the regional biobank in La Reunion University Hospital. She has taken part in sanitary crisis management such as H1N1 influenza and Mers CoV. She is the author of 33 international publications and has given more than 400 hours of class to medical, nurse, midwife and biology students. Nowadays, she works in the microbiology department at Cerba Laboratory, Saint-Ouen l’Aumône, and works on emerging diseases, HIV, arbovirus infections and vaccines.Message Presenter
Stéphanie Haim-Boukobza, PhD Biologist, Cerba Research
In addition to obtaining a PhD in the Virology lab of Pitié Salpètriere, and gathering hospital and university experience as a virologist, Stephanie Haim-Boukobza has also worked in French private labs. She has been with Cerba since 2017 and became the Head of Infectology in 2018. Ever since, she has been working on subjects like microbiome, hepatitis, papillomavirus, etc.Message Presenter
Yan Meng, Ph.D. FACMG, Laboratory Director, Fulgent Genetics
Yan Meng, PhD, FACMG is a laboratory director, clinical molecular geneticist, who joined Fulgent Genetics in Apr, 2019. Before joining Fulgent Genetics, she was Director of Clinical molecular genetics at Wuxi NextCODE Genomics since 2015. Dr. Meng is bringing her combination of expertise in computer science, bioinformatics, and clinical molecular genetics into transforming clinical diagnostics and translating genomics into medicine.
Dr. Meng completed her training at Harvard Genetics Training program in Clinical molecular genetics in June, 2015. From 2009 to 2015, she worked at the Broad institute of MIT and Harvard as statistical geneticist, on large consortium projects funded by NIH, including Candidate-gene Association Resource (CARe) study and Genotype-Tissue Expression (GTEx) project.
Dr. Meng received her PhD in Bioinformatics from the Boston University in 2007 and did post-doctoral research in GWAS in psychiatric genetics at Massachusetts General Hospital. She received a B.S. degree in Biology from Nankai University in China, a MS.c degree in Biology from McGill University, and a M.Sc degree in Computer Science from Concordia University in Canada. She has authored more than 30 peer-reviewed publications on the variety of topics ranging from genetics of model organism, statistical methods, to human genetics of complex diseases.Message Presenter
Who Should Attend?
- R&D managers
- Clinical trial managers
What You Will Learn
What will we learn in this webinar?
- Which Covid-19 tests are available
- What the limits of each test is
- Which tests you should choose for your research
- Covid-19 mutation and the obstacles we face
Cerba Research provides the highest quality specialized laboratory and diagnostic solutions while leveraging patient data and scientific insight to shape and advance clinical trials. With our global footprint and access to leading regional labs, data, patients, technology, and partnered resources, we support global biotech, pharma, and IVD organizations to improve the lives of patients around the world.
From the translation of preclinical to clinical, through commercialization, our expert scientists collaborate with you to optimize your therapeutic development and obtain critical insights earlier. We help accelerate your therapies through the development of highly specialized custom assays, deep biomarker expertise, and a passion for scientific innovation across complex therapeutic areas. Our global network of leading, specialty laboratories ensures you have access to quality data and can reach your patients. Together, we’ll improve patients’ lives around the globe.